Trial reportDrug and alcohol dependence2014
A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone.
Trial report in Drug and alcohol dependence, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00218023 (Screening Medications for Cocaine Cessation and Relapse Prevention), which is not on this map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Screening Medications for Cocaine Cessation and Relapse Prevention
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis.Psychopharmacology · 2020Pooled it
- Dopamine agonists for the treatment of cocaine dependence.The Cochrane database of systematic reviews · 2015Pooled it
- The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder.Journal of addiction medicineGuideline
- Pregnenolone reduces provoked craving and cocaine use in men and women with cocaine use disorder: A pilot trial.Drug and alcohol dependence · 2025Trial
- Mixed amphetamine salts-extended release (MAS-ER) as a behavioral treatment augmentation strategy for cocaine use disorder: A randomized clinical trial.Experimental and clinical psychopharmacology · 2024Trial
- Cocaine abstinence during the "critical period" of a contingency management trial predicts future abstinence in people with cocaine use disorder.Drug and alcohol dependence · 2023Trial
- Cocaine-specific speed-accuracy trade-off during anti-saccade testing differentiates patients with cocaine use disorder who achieve initial abstinence during treatment.Journal of psychopharmacology (Oxford, England) · 2021Trial
- Anhedonia Is Associated with Poorer Outcomes in Contingency Management for Cocaine Use Disorder.Journal of substance abuse treatment · 2017Trial
- A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence.Drug and alcohol dependence · 2015Trial
- Repurposing semaglutide as an adjunctive treatment for cocaine use disorder: protocol for a randomised controlled trial.BMJ open · 2026Article
- Synergistic effects of levo-tetrahydropalmatine and low-dose naltrexone on nicotine conditioned place preference in mice: a dual-target strategy based on dopamine and opioid systems.Frontiers in pharmacology · 2026Article
- Cocaine seeking and consumption are oppositely regulated by mesolimbic dopamine in male rats.Nature communications · 2025Article
- The late positive potential predicts contingency management outcomes for cocaine use disorder.Drug and alcohol dependence · 2025Article
- The Unsolved Problem of Attrition Rates on Randomized Clinical Trials for Cocaine Use Disorders: A Scoping Review.Substance use & addiction journal · 2025Article
- Continuing Increase in Stimulant Dependence - Time to Implement Medical Treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2022Article
- A serotonergic biobehavioral signature differentiates cocaine use disorder participants administered mirtazapine.Translational psychiatry · 2022Article
- Modafinil Does Not Reduce Cocaine Use in Methadone-Maintained Individuals.Drug and alcohol dependence reports · 2022Article
- Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Review
- Helpful or Harmful? The Therapeutic Potential of Medications with Varying Degrees of Abuse Liability in the Treatment of Substance Use Disorders.Current addiction reports · 2022Review
- Modafinil reduces smoked cocaine self-administration in humans: effects vary as a function of cocaine 'priming' and cost.Drug and alcohol dependence · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundCocaine pharmacotherapy trials are often confounded by considerable variability in baseline cocaine-use levels, obscuring possible medication efficacy. Testing the feasibility of using a prerandomization, abstinence-induction protocol, we screened three candidate medications to explore treatment response in patients who did, or did not, achieve abstinence during an extended baseline phase.
methodEligible treatment-seeking, cocaine-dependent subjects entered a 4-week baseline period (Phase I) with high-value abstinence contingent vouchers and two motivational interviewing sessions, followed by a 12-week medication trial (Phase II) with random assignment stratified on Phase I abstinence status to (1) modafinil (400mg/d), (2) levodopa/carbidopa (800/200mg/d), (3) naltrexone (50mg/d), or (4) placebo. Treatment consisted of thrice-weekly clinic visits for urine benzoylecgonine testing and weekly cognitive behavioral therapy with contingency management targeting medication compliance.
resultsOf the 118 subjects enrolled, 81 (80%) completed Phase I, with 33 (41%) achieving abstinence, defined a priori as 6 consecutive cocaine-negative urines. Tests of the interaction of each medication (active versus placebo) by baseline status (abstinent versus nonabstinent) permitted moderator effect analysis. Overall, baseline abstinence predicted better outcome. Cocaine-use outcomes for levodopa and naltrexone treatment differed as a function of Phase I abstinence status, with both medications producing benefit in nonabstinent but not baseline-abstinent subjects. There was no evidence of a moderator effect for modafinil.
conclusionsThe two-phase screening trial demonstrated that subgrouping of patients with respect to baseline abstinence status is feasible and clinically useful for exploring cocaine cessation and relapse-prevention effects of candidate medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.